Fabienne J. Santel, M.D.
Dr. Fabienne J. Santel is a medical officer at the National Institute on Minority Health and Health Disparities. She alternately serves as a program officer or project scientist on a diverse portfolio of grants related to the identification of factors behind health disparities in underserved and vulnerable populations, and the development of interventions and strategies to reduce these disparities.
Dr. Santel has worked as an internist in both primary care and hospital settings. Before coming to NIMHD, Dr. Santel spent 12 years as a senior medical officer at the Food and Drug Administration Center for Devices and Radiological Health (FDA CDRH). At FDA, she served as a clinical reviewer, compliance officer, and policy analyst with expertise in the field of good clinical practices for medical device clinical trials.
Dr. Santel earned her medical degree from the State University of New York Downstate Medical Center. She completed a residency in internal medicine at the Albert Einstein College of Medicine Jacobi Medical Center, followed by a research fellowship at Jacobi through the Empire Clinical Research Investigator Program (ECRIP) evaluating chronic diseases in medically underserved populations. She also earned a Master’s degree in Public Health at Florida Agricultural and Mechanical University.
- Santel, F.J., Bah, I., Kim, K., Lin, J. A., McCracken, J., & Teme, A. (2019). Assessing readability and comprehension of informed consent materials for medical device research: A survey of informed consents from FDA's Center for Devices and Radiological Health. Contemporary clinical trials, 85, 105831. doi.org/10.1016/j.cct.2019.105831
- Abel D., Ulisney K., Santel F.J., Morales J.P. (2017) Regulatory Pathway for Physician-Sponsored Studies Evaluating Endovascular Aortic Repair. In: Oderich G. (eds) Endovascular Aortic Repair. Springer, Cham. doi.org/10.1007/978-3-319-15192-2_17
- Hailpern, S. M., Santel, F.J., Mazurek, J. A., Ramirez, S., Remick, J. D., Klein, J., Schubart, U. K., & Nordin, C. W. (2014). Hemoglobin A1c less than 6.5% on admission increases risk for in-hospital and 1-year mortality in patients with diabetes and chest pain. Cardiovascular Endocrinology, 3(3), 85-91. DOI: 10.1097/XCE.0000000000000033
Page updated January 21, 2021